Screener
Kymera Therapeutics KYMR Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
FAQ
- What is Kymera Therapeutics's operating lease liabilities (total)?
- Kymera Therapeutics (KYMR) reported operating lease liabilities (total) of $76.14M in Q2 2026.
- How has Kymera Therapeutics's operating lease liabilities (total) changed year-over-year?
- Kymera Therapeutics's operating lease liabilities (total) decreased by 6.7% year-over-year, from $81.6M to $76.14M.
- What is the long-term trend for Kymera Therapeutics's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Kymera Therapeutics's operating lease liabilities (total) has grown at a 36.4% compound annual growth rate (CAGR), from $16.7M to $78.98M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.
Ask your AI about Kymera Therapeutics's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude